Campanati Anna, Esposito Maria, Caldarola Giacomo, Cacciapuoti Sara, Fabbrocini Gabriella
Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
Dermatology - Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Drugs Context. 2024 Oct 9;13. doi: 10.7573/dic.2023-11-5. eCollection 2024.
A fixed-dose combination of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam (Enstilar, LEO Pharma) is the only topical therapy approved for the acute (reactive) and proactive management of psoriasis. Although treatment with Cal/BD foam has been characterized in a clinical context, further evidence is needed to determine its optimal use in clinical practice. A group of experts discussed the value of the Cal/BD foam as a topical treatment for mild-to-moderate psoriasis in combination with systemic treatments. The reported experiences support effectiveness of the Cal/BD foam in daily clinical practice, with an improvement in patient quality of life.
钙泊三醇0.005%/二丙酸倍他米松0.064%（Cal/BD）气雾剂泡沫（恩斯梯拉，LEO制药公司）的固定剂量组合是唯一被批准用于银屑病急性（反应性）和预防性治疗的局部疗法。尽管Cal/BD泡沫治疗已在临床背景下得到描述，但仍需要进一步的证据来确定其在临床实践中的最佳使用方法。一组专家讨论了Cal/BD泡沫作为轻度至中度银屑病局部治疗联合全身治疗的价值。报告的经验支持Cal/BD泡沫在日常临床实践中的有效性，可改善患者的生活质量。
